19
DRUG ELUTING BALLOON ELUTAX Dr. med. Alexander Ruebben

Drug Eluting Balloon

Embed Size (px)

DESCRIPTION

A closer look to the ELUTAX Drug Eluting Balloon

Citation preview

Page 1: Drug Eluting Balloon

DRUG ELUTING BALLOON

ELUTAX

Dr. med. Alexander Ruebben

Page 2: Drug Eluting Balloon

AACHEN RESONANCE FACTS

Page 3: Drug Eluting Balloon

WHICH TECHNIQUE IS USED TODAYto Free Paclitaxel and to ensure Up-take

• Mixture of Paclitaxel with Hydrophilic and Lipophilic Additive:

• Sequent Please - BBraun• In.Pact Amphirion - Invatec

• Mixture of Paclitaxel and Shelac solution• DIOR (2nd Gen) - Eurocor

• Matrix of pure Paclitaxel „Ice“ and „Snow“• ELUTAX – Aachen Resonance

Page 4: Drug Eluting Balloon

What does this mean?

• A mixture of different compounds with paclitaxel guarantees a diffusion from the balloon and an uptake into the vessel

Draw Back!!!!• The release begins once the catheter is in

contact with fluids!!!!!!!!• The amount of drug uptake depends on the

duration of the procedure!

Page 5: Drug Eluting Balloon

Different Drug Loss of DEB during InterventionDrug-formulation - Pure Drug

The SequentPlease loses upto 50% of Drug every 10 secondsThe ELUTAX loses max. 10% during the whole procedureTests were performed together with the Radiology Department, University of Homburg, Prof Buecker, the reference Balloon was the SequentPlease from BBraun against ELUTAX from Aachen Resonance. Data unpublished

0 sec 10 sec 20 sec 30 sec 40 sec 50 sec

Page 6: Drug Eluting Balloon

ELUTAX

• Homogenous coating• Even and Consistent coating of inflated Balloons• Drug Matrix of pure Paclitaxel (two layers SNOW and ICE) • Balloon with 360 Degree coating coverage• Minimal Drug lost during passage in the body • Minimal Drug lost from the balloon surface during maneuver

or inflation• Reliable quantitative Drug deposition into the vessel wall• Safe Drug Transfer• No additional substances• No Cracks

Page 7: Drug Eluting Balloon

ELUTAX3-D Mirco Structure

Page 8: Drug Eluting Balloon

ELUTAXLow profile folding technique

Page 9: Drug Eluting Balloon

ELUTAXTapered flexible tip

Page 10: Drug Eluting Balloon

12h 0,19 9,80 7.79 8,08 0,74

proximalreference

proximaldilatedsequence

distalreference

middledilatedsequence

distaldilatedsequence

1 2 3 4 5

1 2 3 4 5µmol/l

Arterial tissue paclitaxel concentration after ELUTAX balloon dilatation

1h 6.9 58,7 66,2 79,2 7.0.

proximalreference

proximaldilatedsequence

distalreference

middledilatedsequence

distaldilatedsequence

1 2 3 4 5

1 2 3 4 5 µmol/l

ELUTAX

Gyöngyösi

Page 11: Drug Eluting Balloon

Pharmacokinetics of ELUTAX

1 min 60 min 12 hours

Dior 1 gen.

Elutax 2nd gen.For at least 12 hours we have a therapeutic dose in the vessel wall!

Gyöngyösi

Page 12: Drug Eluting Balloon

Pharmacokinetics ofDifferent Concepts

after contact 0 min 1 h 12 h 24 h 48 h

Drug concentration in the tissue

micromol/lData available from Prospect of Manufacturer

Page 13: Drug Eluting Balloon

ElutaxElutax

The tissue The tissue concentration after one concentration after one hour seems to be hour seems to be optimal!!!!optimal!!!!

(tissue concentration of paclitaxel effective from 56 nM to 50 µM, toxic effect over 100 µM in cell culture, Axel et al. Circulation 1997)

70 micromol/l70 micromol/l

Gyöngyösi

Page 14: Drug Eluting Balloon

Products with toxic tissue Paclitaxel concentration longer than one hour

Sequent PleaseDior current coating

(tissue concentration of paclitaxel effective from 56 nM to 50 µM, toxic effect over 100 µM in cell culture, Axel et al. Circulation 1997)

Page 15: Drug Eluting Balloon

Sequent Please

Page 16: Drug Eluting Balloon

Eurocor DIOR new coating

Page 17: Drug Eluting Balloon

Which Problems can occur, if too toxic Drug-levels are applied:?

Page 18: Drug Eluting Balloon

Iasis CE-trial (Bulgaria)In-Stent restenosis, with angiographic follow-up

after 6 months:

performed by Dr. Ivan Manukov, Head of Department

Interventional Cardiology, UMBAL Sveti Georgi Hospital, Plovdiv, Bulgaria

43 patients treated with Elutax

0% restenosis

Page 19: Drug Eluting Balloon

Iasis PE-trial (Bulgaria-Italy)Peripheral USE with color doppler follow-up

after 6 months:

Carotis, Vertebralis, Subclavia, Renal, AV Fistula, Femoral, BTK, BY Pass graft

39 patients treated with ELUTAX

2 % occlusion7 % non significant Stenosis